Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ABEONA THERAPEUTICS INC.

Get SEC filing alerts via email and in your feed for ABEONA THERAPEUTICS INC.

ABEO

ABEONA THERAPEUTICS INC.

About ABEONA THERAPEUTICS INC.

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cell and gene therapies for life-threatening genetic diseases. Its lead product, pz-cel, targets recessive dystrophic epidermolysis bullosa (RDEB) and has shown promising clinical results. With a strong emphasis on advanced manufacturing capabilities and strategic partnerships, Abeona aims to address significant unmet medical needs in rare diseases, leveraging its proprietary AIM™ capsid technology for future therapies.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from ABEONA THERAPEUTICS INC.

1
1
ABEONA THERAPEUTICS INC. Abeona Therapeutics Reports $8.7M Product Revenue and $17.1M Net Loss in Q1 2026

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
ABEONA THERAPEUTICS INC. Abeona Therapeutics Reports $5.8M Revenue and $71.2M Net Income in 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
ABEONA THERAPEUTICS INC. Abeona Therapeutics Reports $91.6 Million Net Income and Significant Asset Growth in Latest 10-Q

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
ABEONA THERAPEUTICS INC. Abeona Therapeutics Reports $400,000 Revenue and $108.8 Million Net Income for Quarter Ending June 30, 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
ABEONA THERAPEUTICS INC. Abeona Therapeutics Reports $12M Net Loss in Q1 2025, FDA Approves ZEVASKYN™

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
ABEONA THERAPEUTICS INC. Abeona Therapeutics Reports $63.7 Million Net Loss and Nil Revenue for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
ABEONA THERAPEUTICS INC. Abeona Therapeutics Reports Significant Financial Growth and Advancements in Lead Gene Therapy Program

Via official filing (AI summary) | over 1 year ago | 0 comments